TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Stock · Health Care

$17.41+$0.00 (+0.00%)as of market close, Aug 13, 2026

☾ After hours:$17.39+0.00%3:59 PM ET

CompareLLYUNHJNJABBVISRGTMO

TAK financial statements

The full income statement, balance sheet, and cash-flow statement for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2019-03 1.93B2020-03 3.12B2021-03 3.15B2022-03 3.15B2023-03 3.14B2024-03 3.16B2025-03 3.21B2025-12 3.21B2026-03 3.15B+62.9% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeYoYQoQFiguresAs-reported fiscal years.

Line item	FY2026	FY2025	FY2024	FY2023	FY2022
Income Statement	as ofMar 31 ’26	as ofMar 31 ’25	as ofMar 31 ’24	as ofMar 31 ’23	as ofMar 31 ’22
Revenue	29.8B YoY-0.9%	30.0B YoY+2.0%	29.5B YoY-1.0%	29.7B YoY-6.4%	31.8B YoY+5.3%
Cost of revenue	10.4B YoY+0.2%	10.4B YoY+5.1%	9.86B YoY+7.3%	9.19B YoY-6.7%	9.85B YoY+5.0%
Research & development	4.47B YoY-6.7%	4.79B YoY-5.0%	5.04B YoY+7.8%	4.68B YoY-0.1%	4.68B YoY+8.9%
Operating income	41.1M YoY-98.2%	2.25B YoY+51.9%	1.48B YoY-59.2%	3.62B YoY-11.7%	4.10B YoY-14.6%
Interest expense	2.36B YoY+71.6%	1.38B YoY-9.3%	1.52B YoY+21.2%	1.25B YoY-15.5%	1.48B YoY-36.8%
Pre-tax income	-941M YoY-182.0%	1.15B YoY+214.8%	365M YoY-86.8%	2.77B YoY+2.9%	2.69B YoY-22.1%
Income tax	64.6M YoY-85.3%	439M YoY+169.5%	-631M YoY-247.3%	429M YoY-33.5%	644M YoY+787.5%
	-1.01B YoY-241.8%	709M YoY-28.8%	996M YoY-57.5%	2.34B YoY+14.3%	2.05B YoY-42.3%
Net income to common	-1.01B YoY-242.3%	708M YoY-28.9%	995M YoY-57.5%	2.34B YoY+14.3%	2.05B YoY-42.3%
	-$0.32 YoY-245.1%	$0.22 YoY-30.0%	$0.31 YoY-57.8%	$0.75 YoY+14.9%	$0.65 YoY-42.4%
EPS (basic)	-$0.32 YoY-242.7%	$0.22 YoY-29.5%	$0.32 YoY-57.8%	$0.75 YoY+15.2%	$0.65 YoY-42.3%
	3.15B YoY-0.2%	3.16B YoY+0.9%	3.13B YoY+0.8%	3.10B YoY-0.7%	3.13B YoY+0.1%
	3.15B YoY-1.9%	3.21B YoY+1.6%	3.16B YoY+0.7%	3.14B YoY-0.5%	3.15B YoY+0.2%
Dividends per share	$0.66 YoY+5.9%	$0.62 YoY-1.6%	$0.63 YoY-3.9%	$0.65 YoY-18.4%	$0.80 YoY-5.7%
Balance Sheet	as ofMar 31 ’26	as ofMar 31 ’25	as ofMar 31 ’24	as ofMar 31 ’23	as ofMar 31 ’22
	19.5B YoY+15.8%	16.8B YoY-0.5%	16.9B YoY-6.5%	18.1B YoY-15.2%	21.3B YoY-13.3%
Cash & equivalents	3.75B YoY+46.0%	2.57B YoY-15.1%	3.02B YoY-24.8%	4.02B YoY-42.4%	6.98B YoY-20.2%
Accounts receivable	5.32B YoY+12.4%	4.73B YoY+7.1%	4.42B YoY-9.8%	4.90B YoY-14.5%	5.73B YoY-19.3%
Inventory	8.80B YoY+8.4%	8.12B YoY+1.6%	7.99B YoY+7.4%	7.44B YoY+6.1%	7.01B YoY+2.6%
	97.7B YoY+2.9%	95.0B YoY-4.8%	99.8B YoY-5.2%	105B YoY-2.8%	108B YoY-7.4%
Property, plant & equipment	—	—	—	12.8B YoY-2.0%	13.0B YoY-1.3%
Goodwill	36.6B YoY+3.1%	35.5B YoY-0.7%	35.7B YoY-1.1%	36.1B YoY-0.3%	36.2B YoY-0.9%
Total non-current assets	78.3B YoY+0.1%	78.2B YoY-5.7%	82.9B YoY-4.9%	87.2B YoY+0.2%	87.0B YoY-5.9%
Total current liabilities	17.8B YoY+6.8%	16.7B YoY+9.4%	15.3B YoY-18.4%	18.7B YoY+6.1%	17.6B YoY+9.8%
	50.9B YoY+4.4%	48.8B YoY-5.8%	51.8B YoY-9.7%	57.3B YoY-6.9%	61.6B YoY-12.1%
Long-term debt	27.5B YoY+4.1%	26.4B YoY-10.6%	29.6B YoY-3.0%	30.5B YoY-10.4%	34.0B YoY-18.6%
	46.8B YoY+1.2%	46.2B YoY-3.7%	48.0B YoY+0.3%	47.9B YoY+2.6%	46.7B YoY-0.4%
Total equity incl. non-controlling	46.8B YoY+1.2%	46.3B YoY-3.7%	48.1B YoY+0.3%	47.9B YoY+2.5%	46.7B YoY-0.4%
Cash Flow	as ofMar 31 ’26	as ofMar 31 ’25	as ofMar 31 ’24	as ofMar 31 ’23	as ofMar 31 ’22
	6.88B YoY-0.7%	6.93B YoY+40.1%	4.95B YoY-31.4%	7.22B YoY-27.8%	9.99B YoY+4.8%
Depreciation & amortization	4.77B YoY-4.5%	4.99B YoY-0.7%	5.03B YoY+2.5%	4.91B YoY-5.5%	5.19B YoY-1.7%
Acquisitions	0.00	0.00	0.00	0.00	0.00
Long-term debt issued	3.87B YoY-42.3%	6.72B YoY+872.5%	691M YoY+24.7%	554M YoY-75.0%	2.22B YoY-80.1%
Long-term debt repaid	1.32B YoY-84.7%	8.66B YoY+290.8%	2.22B YoY-15.8%	2.63B YoY-63.5%	7.21B YoY-53.7%
Common stock issued	7.84M YoY-96.7%	237M YoY+6741.3%	3.47M YoY+186.3%	1.21M YoY-99.4%	197M YoY+47400.1%
Common stock repurchased	341M YoY+0.2%	340M YoY+1982.4%	16.4M YoY-91.8%	200M YoY-71.7%	707M YoY+3400.7%
Dividends paid	2.07B YoY+3.9%	1.99B YoY-0.0%	1.99B YoY-3.3%	2.06B YoY-18.7%	2.53B YoY-5.5%
Valuation Ratios	as ofMar 31 ’26	as ofMar 31 ’25	as ofMar 31 ’24	as ofMar 31 ’23	as ofMar 31 ’22
Market cap	58.3B YoY+22.2%	47.7B YoY+9.5%	43.6B YoY-15.7%	51.7B YoY+14.6%	45.2B YoY-21.4%
P/E	—	67.3× YoY+261.4%	18.6× YoY-15.7%	22.1× YoY+0.2%	22.1× YoY+36.2%
P/S	2.0× YoY+23.3%	1.6× YoY+8.4%	1.5× YoY-15.7%	1.7× YoY+22.3%	1.4× YoY-25.3%
P/B	1.2× YoY+20.7%	1.0× YoY+13.4%	0.9× YoY-15.7%	1.1× YoY+11.7%	1.0× YoY-21.1%
	—	1.5% YoY-72.3%	5.4% YoY+18.6%	4.5% YoY-0.2%	4.5% YoY-26.6%
	3.5% YoY-15.0%	4.2% YoY-8.0%	4.5% YoY+14.0%	4.0% YoY-29.1%	5.6% YoY+20.2%
Source filing	20-F	20-F	20-F	20-F	20-F

About this data

Source: TAK's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TAK filings on SEC EDGAR → Not investment advice.